Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
about
Should individual PI3 kinase isoforms be targeted in cancer?Somatic mosaic activating mutations in PIK3CA cause CLOVES syndromeEmerging common themes in regulation of PIKKs and PI3KsTumours with PI3K activation are resistant to dietary restrictionKnockin of mutant PIK3CA activates multiple oncogenic pathwaysTransforming properties of YAP, a candidate oncogene on the chromosome 11q22 ampliconSomatic mutation and gain of copy number of PIK3CA in human breast cancer.The Role of Genomic Profiling in Advanced Breast Cancer: The Two Faces of JanusThe PI3K/AKT Pathway and Renal Cell CarcinomaDiverse mechanisms of AKT pathway activation in human malignancyThe azaindole framework in the design of kinase inhibitorsCIViC databaseMechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunitThe structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutationsAutoinhibition and Phosphorylation-Induced Activation of Phospholipase C-γ IsozymesDiscovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of RapamycinAllelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.PIK3CA mutation is associated with poor survival among patients with metastatic colorectal cancer following anti-EGFR monoclonal antibody therapy: a meta-analysis.Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical dataDrugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeuticsOncogenic mutations of PIK3CA in human cancersLoss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cellsIdentification of novel piperazinylquinoxaline derivatives as potent phosphoinositide 3-kinase (PI3K) inhibitorsActive PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodesThe evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismA Transformation-Defective Polyomavirus Middle T Antigen with a Novel Defect in PI3 Kinase Signaling.Genomic profiling reveals mutational landscape in parathyroid carcinomasThe determinants of head and neck cancer: Unmasking the PI3K pathway mutationsAttenuation of phospholipid signaling provides a novel mechanism for the action of valproic acid.Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase.De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly.Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA.Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation.A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors.Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models.Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models.Defining the blueprint of the cancer genome.Physiological regulation of Akt activity and stability.The PIK3CA gene as a mutated target for cancer therapy.
P2860
Q24309044-15F6097A-CEE4-4859-B450-A86C65077E19Q24608709-06BABC21-D34D-4389-BD02-F466C4583A8DQ24647293-4196A14C-7D44-4ACC-8F2E-4B0E47F1344EQ24650286-93B7F295-3C4A-427C-A7AC-FBDFBA4B8AA7Q24657412-F560828D-D51E-439E-AC2B-008DC57490E2Q24682018-35B6DB6A-96ED-4788-B5FF-929043F828CCQ24813416-3092EB8C-01B0-4D9D-8653-7A9C9C329ACAQ26740184-23FE8AC7-1C67-427D-B2AD-11C8F8BE7F4BQ26800216-A2A0E515-9578-435D-8543-FDFD264B246CQ26851604-1E1152D4-BE3A-4677-96D4-74C96BFAC484Q27013668-CBD1A25A-40CB-439F-B6CC-00B92A758D0FQ27612411-626CE707-F017-4904-9B08-9CA765DC5117Q27646654-2A6ED4D7-D2E1-4B01-A56B-5317621FA02EQ27649316-69048015-E1B6-4280-96BE-AA5689E24477Q27678692-43AF7167-AF98-4A2E-B593-4B66F27AD157Q27684091-76454BC7-1EBD-4799-B663-5B60B8D39845Q27851396-6BCAA06D-73A1-4FF4-96CE-9C82F6DC304FQ27852105-A18D169C-1922-4E44-AE31-5E2DCC24914CQ27853324-E4812D2A-19FD-4AE4-8B7C-B8F1AF91EC81Q28247338-30AAE0B3-A8AC-484A-B5A3-B2FD72A996C5Q28254233-096CE4EB-9E99-4160-B670-1C04107BFBBFQ28284802-1503F60C-A531-4DD3-A963-0E5E1AC59E8AQ28481370-595EF664-C381-4604-BFD4-60D0040C5D8BQ28482245-720AA78F-5196-4B1B-95DE-5A773F457C17Q28730141-EFFE9491-C40B-48BE-AFD4-3803F260ABCEQ29547302-3115B8B1-ABA0-46B3-8C65-10474297284AQ30008815-94487F0E-1D6C-4BB0-B181-B4A588BE3FE8Q30360213-82FD7276-CD4B-4EE1-9C94-BDE074576E7CQ30365726-CD4685D5-626D-43F6-AF9E-2BF1D5E73126Q30479940-6FE79374-B5B6-485E-9F87-49CC6488D8A5Q30492318-FA757996-EBF4-4C90-B2F8-10B6D2B22177Q30647055-610E5BB1-EB69-42A5-8F4D-B25B25EBEA4FQ33292494-F7C3C960-185E-472B-A6CF-3E107DE446AAQ33403197-652117AF-865B-434A-BDEB-FE70F93F29FDQ33420634-28F684FF-9EF5-40F6-AD22-FBFBCEDA630CQ33511579-A4A185BA-21AD-4EE7-88DC-5EC9EE0BDA3BQ33533301-535AC447-1EDB-4A7C-91B1-13BFE9B980E5Q33671802-87109CAC-81F5-4DC4-9AA4-B120634642F7Q33680673-946550AC-FF24-4505-8EB8-13BCC4EA085AQ33699378-4116412B-E720-46BB-AAB2-B79A888D46CC
P2860
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
@ast
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
@en
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
@nl
type
label
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
@ast
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
@en
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
@nl
altLabel
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
@en
prefLabel
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
@ast
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
@en
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.
@nl
P2860
P3181
P356
P1476
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic
@en
P2093
Andreas G Bader
Sohye Kang
P2860
P3181
P356
10.1073/PNAS.0408864102
P407
P50
P577
2005-01-18T00:00:00Z